Overview

Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

Status:
Recruiting
Trial end date:
2025-01-30
Target enrollment:
Participant gender:
Summary
Open-label dose escalation of Ulixertinib combined with fixed dose of hydroxychloroquine.
Phase:
Phase 1
Details
Lead Sponsor:
University of Utah
Collaborator:
BioMed Valley Discoveries, Inc
Treatments:
Hydroxychloroquine